Scios Natrecor
Executive Summary
NDA submitted April 27 for nesiritide for acute congestive heart failure. The NDA for the recombinant b-type natriuretic peptide, the first for the Mountain View, Calif.-based company, was based on a 127-patient Phase III efficacy study that showed a 20% mean reduction in pulmonary capillary wedge pressure at the dose being sought by the company...